Compass Pathways’ (CMPS) Buy Rating Reaffirmed at HC Wainwright

by · The Markets Daily

Compass Pathways (NASDAQ:CMPS – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $70.00 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 432.81% from the company’s current price.

A number of other equities research analysts have also weighed in on CMPS. BTIG Research lifted their target price on Compass Pathways from $14.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday. Royal Bank Of Canada upped their price objective on shares of Compass Pathways from $21.00 to $22.00 and gave the stock an “outperform” rating in a research note on Thursday, May 14th. Wall Street Zen upgraded shares of Compass Pathways from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Wolfe Research reissued an “outperform” rating on shares of Compass Pathways in a research report on Tuesday. Finally, Oppenheimer restated an “outperform” rating and issued a $20.00 price target on shares of Compass Pathways in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $24.15.

Get Our Latest Report on CMPS

Compass Pathways Trading Up 1.1%

Compass Pathways stock traded up $0.15 during trading hours on Wednesday, hitting $13.14. The company had a trading volume of 3,328,715 shares, compared to its average volume of 3,711,231. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.32 and a current ratio of 3.32. The firm has a market cap of $1.77 billion, a P/E ratio of -4.18 and a beta of 2.47. The company has a 50-day moving average price of $11.70 and a two-hundred day moving average price of $8.48. Compass Pathways has a 1 year low of $3.45 and a 1 year high of $15.40.

Compass Pathways (NASDAQ:CMPS – Get Free Report) last issued its earnings results on Wednesday, May 13th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. On average, sell-side analysts anticipate that Compass Pathways will post -1.24 earnings per share for the current year.

Institutional Investors Weigh In On Compass Pathways

A number of institutional investors have recently added to or reduced their stakes in CMPS. Seven Fleet Capital Management LP lifted its position in shares of Compass Pathways by 295.1% during the first quarter. Seven Fleet Capital Management LP now owns 158,021 shares of the company’s stock valued at $874,000 after buying an additional 118,021 shares during the last quarter. Parallel Advisors LLC boosted its holdings in shares of Compass Pathways by 8,450.6% in the 1st quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock valued at $40,000 after buying an additional 7,183 shares in the last quarter. Vivo Capital LLC purchased a new position in shares of Compass Pathways in the 1st quarter worth approximately $1,106,000. Bank of America Corp DE grew its position in shares of Compass Pathways by 43.8% in the 1st quarter. Bank of America Corp DE now owns 32,332 shares of the company’s stock worth $179,000 after buying an additional 9,853 shares during the last quarter. Finally, EverSource Wealth Advisors LLC raised its stake in shares of Compass Pathways by 67.7% during the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock worth $26,000 after acquiring an additional 1,920 shares in the last quarter. Institutional investors own 46.19% of the company’s stock.

Compass Pathways News Roundup

Here are the key news stories impacting Compass Pathways this week:

  • Positive Sentiment: Evercore upgraded Compass Pathways from in-line to outperform and set a $21 price target, signaling meaningful upside potential as investors reassess the stock. Article Title
  • Positive Sentiment: The company reported six-month Phase 3 data from its COMP006 trial showing COMP360’s rapid onset and durable effect in treatment-resistant depression, a key step toward strengthening the FDA case for approval. Article Title
  • Positive Sentiment: Morgan Stanley reaffirmed its overweight rating and BTIG raised its price target to $25 with a buy rating, reinforcing bullish analyst sentiment after the new trial update. Article Title
  • Neutral Sentiment: Additional coverage focused on the new data review and the company’s progress toward an FDA filing, but did not add materially new fundamentals beyond the trial results and analyst reactions. Article Title
  • Negative Sentiment: Some commentary noted the stock’s reaction has been somewhat muted relative to the strength of the data, suggesting investors may still be waiting for regulatory clarity before assigning a higher valuation. Article Title

About Compass Pathways

(Get Free Report)

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.

See Also